FI905326A0 - Menetelmä lääkeaineina käyttökelpoisten imidatso/4,5-b/kinolinyylioksialkaanihappoamidien valmistamiseksi - Google Patents

Menetelmä lääkeaineina käyttökelpoisten imidatso/4,5-b/kinolinyylioksialkaanihappoamidien valmistamiseksi

Info

Publication number
FI905326A0
FI905326A0 FI905326A FI905326A FI905326A0 FI 905326 A0 FI905326 A0 FI 905326A0 FI 905326 A FI905326 A FI 905326A FI 905326 A FI905326 A FI 905326A FI 905326 A0 FI905326 A0 FI 905326A0
Authority
FI
Finland
Prior art keywords
imidazo
drug
preparation
acid amides
amides useful
Prior art date
Application number
FI905326A
Other languages
English (en)
Swedish (sv)
Other versions
FI92697B (fi
FI92697C (fi
Inventor
Nicholas Meanwell
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of FI905326A0 publication Critical patent/FI905326A0/fi
Publication of FI92697B publication Critical patent/FI92697B/fi
Application granted granted Critical
Publication of FI92697C publication Critical patent/FI92697C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
FI905326A 1989-11-01 1990-10-29 Menetelmä lääkeaineina käyttökelpoisten imidatso/4,5-b/kinolinyylioksialkaanihappoamidien valmistamiseksi FI92697C (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/430,228 US4943573A (en) 1989-11-01 1989-11-01 Imidazo[4,5-b]quinolinyloxyalkanoic acid amides with enhanced water solubility
US43022889 1989-11-01

Publications (3)

Publication Number Publication Date
FI905326A0 true FI905326A0 (fi) 1990-10-29
FI92697B FI92697B (fi) 1994-09-15
FI92697C FI92697C (fi) 1994-12-27

Family

ID=23706624

Family Applications (1)

Application Number Title Priority Date Filing Date
FI905326A FI92697C (fi) 1989-11-01 1990-10-29 Menetelmä lääkeaineina käyttökelpoisten imidatso/4,5-b/kinolinyylioksialkaanihappoamidien valmistamiseksi

Country Status (20)

Country Link
US (1) US4943573A (fi)
EP (1) EP0426180A3 (fi)
JP (1) JPH03169880A (fi)
KR (1) KR910009705A (fi)
CN (1) CN1025999C (fi)
AU (1) AU639033B2 (fi)
CA (1) CA2027935A1 (fi)
EG (1) EG19372A (fi)
FI (1) FI92697C (fi)
HU (1) HU209305B (fi)
IE (1) IE61579B1 (fi)
IL (1) IL96167A (fi)
MY (1) MY105308A (fi)
NO (1) NO175531C (fi)
NZ (1) NZ235868A (fi)
OA (1) OA09323A (fi)
PT (1) PT95765A (fi)
RU (1) RU2041210C1 (fi)
YU (1) YU205590A (fi)
ZA (1) ZA908725B (fi)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943573A (en) * 1989-11-01 1990-07-24 Bristol-Myers Squibb Company Imidazo[4,5-b]quinolinyloxyalkanoic acid amides with enhanced water solubility
PH31245A (en) * 1991-10-30 1998-06-18 Janssen Pharmaceutica Nv 1,3-Dihydro-2H-imidazoÄ4,5-BÜ-quinolin-2-one derivatives.
US5348960A (en) * 1992-04-03 1994-09-20 Bristol-Myers Squibb Company Imidazo[4,5-b]quinolinyl oxy alkyl tetrazolyl piperidine derivatives
US5158958A (en) * 1992-04-03 1992-10-27 Bristol-Myers Squibb Company Imidazo[4,5-b]quinolinyl oxy alkyl sulfonyl piperidine derivatives
US5196428A (en) * 1992-04-03 1993-03-23 Bristol-Myers Squibb Company Imidazo[4,5-b]qinolinyl oxy alkyl ureas
US5208237A (en) * 1992-04-03 1993-05-04 Bristol-Meyers Squibb Company 7-oxypropylsulfonamido-imidazo[4,5-b]quinolin-2-ones
US5552267A (en) * 1992-04-03 1996-09-03 The Trustees Of Columbia University In The City Of New York Solution for prolonged organ preservation
TW593317B (en) 1993-06-21 2004-06-21 Janssen Pharmaceutica Nv Positive cardiac inotropic and lusitropic pyrroloquinolinone derivatives
US5672622A (en) * 1994-04-21 1997-09-30 Berlex Laboratories, Inc. Treatment of multiple sclerosis
US6060501A (en) * 1994-06-02 2000-05-09 Schering Aktiengesellschaft Combined treatment of multiple sclerosis
WO1996005202A1 (fr) * 1994-08-17 1996-02-22 Nippon Hypox Laboratories Inc. Derive de l'imidazoquinoleine
US5798767A (en) * 1996-03-15 1998-08-25 Rendition, Inc. Method and apparatus for performing color space conversion using blend logic
SE9902987D0 (sv) * 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
US20030186963A1 (en) * 2001-09-14 2003-10-02 Dorwald Florencio Zaragoza Substituted piperidines
WO2003031432A1 (en) * 2001-10-12 2003-04-17 Novo Nordisk A/S Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
US7064135B2 (en) 2001-10-12 2006-06-20 Novo Nordisk Inc. Substituted piperidines
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2651862A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
US8227603B2 (en) * 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
US8299248B2 (en) * 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
AU2007281468B2 (en) * 2006-08-02 2012-12-06 Cytokinetics, Incorporated Certain chemical entities, compositions and methods
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US7851484B2 (en) * 2007-03-30 2010-12-14 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
GB0808967D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substitute quinazolines
GB0808947D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substituted quinazolines
GB0808968D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substitute quinazolines
GB0808952D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substituted quinazolines
ES2627848T3 (es) 2008-06-04 2017-07-31 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN103764672A (zh) 2011-03-01 2014-04-30 辛纳吉制药公司 制备鸟苷酸环化酶c激动剂的方法
CA2849213A1 (en) 2011-07-13 2013-01-17 Cytokinetics, Inc. Combination of riluzole and ck-2017357 for treating als
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
EP2958577A2 (en) 2013-02-25 2015-12-30 Synergy Pharmaceuticals Inc. Guanylate cyclase receptor agonists for use in colonic cleansing
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
KR102272746B1 (ko) 2013-06-05 2021-07-08 보슈 헬스 아일랜드 리미티드 구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법
CA2920856A1 (en) 2013-08-09 2015-02-12 Ardelyx, Inc. Ph modulating compounds for inhibiting gastrointestinal phosphate uptake
JP2022533251A (ja) 2019-05-21 2022-07-21 アルデリックス， インコーポレイテッド 患者において血清リン酸塩を低下させるための組み合わせ

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3932407A (en) * 1973-11-19 1976-01-13 Bristol-Myers Company Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones
NL7807507A (nl) * 1977-07-25 1979-01-29 Hoffmann La Roche Tricyclische verbindingen.
US4490371A (en) * 1983-02-16 1984-12-25 Syntex (U.S.A.) Inc. N,N-Disubstituted-(2-oxo-1,2,3,5-tetrahydroimidazo-[2,1-B]quinazolinyl)oxyalkylamides
JPS60193991A (ja) * 1984-02-15 1985-10-02 シンテツクス（ユー・エス・エイ）インコーポレイテツド イミダゾキナゾリニルオキシアルキルアミド誘導体
US4668686A (en) * 1985-04-25 1987-05-26 Bristol-Myers Company Imidazoquinoline antithrombrogenic cardiotonic agents
US4775674A (en) * 1986-05-23 1988-10-04 Bristol-Myers Company Imidazoquinolinylether derivatives useful as phosphodiesterase and blood aggregation inhibitors
US4701459A (en) * 1986-07-08 1987-10-20 Bristol-Myers Company 7-amino-1,3-dihydro-2H-imidazo[4,5-b]quinolin 2-ones and method for inhibiting phosphodiesterase and blood platelet aggregation
US4943573A (en) * 1989-11-01 1990-07-24 Bristol-Myers Squibb Company Imidazo[4,5-b]quinolinyloxyalkanoic acid amides with enhanced water solubility

Also Published As

Publication number Publication date
HU906977D0 (en) 1991-05-28
NO904689D0 (no) 1990-10-30
JPH03169880A (ja) 1991-07-23
AU639033B2 (en) 1993-07-15
EP0426180A2 (en) 1991-05-08
EP0426180A3 (en) 1992-01-08
YU205590A (sh) 1992-09-07
NZ235868A (en) 1993-12-23
EG19372A (en) 1994-12-30
IE61579B1 (en) 1994-11-16
NO175531B (no) 1994-07-18
AU6567990A (en) 1991-05-23
PT95765A (pt) 1991-09-13
IE903923A1 (en) 1991-05-08
IL96167A0 (en) 1991-07-18
MY105308A (en) 1994-09-30
HU209305B (en) 1994-04-28
FI92697B (fi) 1994-09-15
CN1051359A (zh) 1991-05-15
KR910009705A (ko) 1991-06-28
HUT56102A (en) 1991-07-29
NO904689L (no) 1991-05-02
ZA908725B (en) 1991-07-31
OA09323A (en) 1992-09-15
FI92697C (fi) 1994-12-27
CA2027935A1 (en) 1991-05-02
RU2041210C1 (ru) 1995-08-09
US4943573A (en) 1990-07-24
IL96167A (en) 1994-11-11
CN1025999C (zh) 1994-09-28
NO175531C (no) 1994-10-26

Similar Documents

Publication Publication Date Title
FI905326A0 (fi) Menetelmä lääkeaineina käyttökelpoisten imidatso/4,5-b/kinolinyylioksialkaanihappoamidien valmistamiseksi
FI871492A (fi) Menetelmä lääkeaineina käyttökelpoisten 2-tiometyyli-substituoitujen 1,4-dihydropyridiinien valmistamiseksi
FI881978A0 (fi) Menetelmä eperisonia sisältävän farmaseuttisen koostumuksen valmistamiseksi
FI891021A0 (fi) Menetelmä lääkeaineina käyttökelpoisten 1,2,4-triatsolijohdannaisten valmistamiseksi
FI881103A (fi) Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi
FI885884A (fi) Menetelmä hitaasti vapautuvan farmaseuttisen koostumuksen valmistamiseksi
FI871294A0 (fi) Menetelmä lääkeaineina käyttökelpoisten milbemysiinin johdannaisten valmistamiseksi
FI890282A (fi) Menetelmä terapeuttisesti käyttökelpoisten 23,24-didehydro-25-hydroksikalsiferolijohdannaisten valmistamiseksi
FI95381C (fi) Menetelmä terapeuttisesti käyttökelpoisten, raseemisten tai optisesti aktiivisten pyrido/1,2-a/pyratsiinien valmistamiseksi
FI893297A (fi) Menetelmä lääkeaineina käyttökelpoisten (atsa)naftaleenisultaamijohdannaisten valmistamiseksi
FI881303A0 (fi) Menetelmä ibuprofeenin valmistamiseksi
FI93106C (fi) Menetelmä lääkeaineina käyttökelpoisten 2-iminobentsotiatsoliinijohdannaisten valmistamiseksi
MA21122A1 (fr) Procede de preparation de derives d'acides aminocarboxyliques bicycliques .
FI902316A0 (fi) Menetelmä valmistaa terapeuttisesti vaikuttavia substituoituja dihydropyrrolitsiiniyhdisteitä
FI93107B (fi) Menetelmä lääkeaineina käyttökelpoisten 2-imino-6-polyfluorialkoksibentsotiatsolijohdannaisten valmistamiseksi
FI895983A0 (fi) Menetelmä lääkeaineina käyttökelpoisten 2-bentsotiatsoliinijohdannaisten valmistamiseksi
PT82802B (en) Process for preparing 1,8 bridged 4-quinolone-3-carboxylic acids useful as medicaments
FI900145A0 (fi) Menetelmä farmaseuttisesti käyttökelpoisten 1,1-diokso-kefem-4-karbotiolihappojohdannaisten valmistamiseksi
FI100799B (fi) Menetelmä terapeuttisesti aktiivisten tetraliinijohdannaisten valmista miseksi
FI901606A0 (fi) Tieno-triatsolo-diatsepiinien sulfonyylijohdosten valmistusmenetelmä
AU5992990A (en) 14,17alpha-etheno- and -ethanoestratrienes, processes for the preparation of these compounds, as well as their use for the production of medicinal agents
FI894119A (fi) Menetelmä isoseriini-N,N-dietikkahapon trinatriumsuolan valmistamiseksi
FI891111A0 (fi) Menetelmä 1,4-dihydropyridiinijohdannaisten valmistamiseksi
GB2272218B (en) Process for the preparation of 2,4,6-triiodo-isophthalic acid bis-(1,3-dihydroxypropylamide) derivatives
FI900098A (fi) Menetelmä lääkeaineena käyttökelpoisten 5H-pyrido/1',2':4,5/tiadiatsino/2,3-a/bentsimidatsoliumjohdannaisten valmistamiseksi

Legal Events

Date Code Title Description
FG Patent granted

Owner name: BRISTOL-MYERS SQUIBB COMPANY

BB Publication of examined application
MM Patent lapsed
MM Patent lapsed

Owner name: BRISTOL-MYERS SQUIBB COMPANY